Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy

被引：1
|
作者：
Aydiner, Adnan [1 ]
Sari, Murat [1 ]
机构：
[1] Istanbul Univ, Inst Oncol, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21212
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [31] A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCTS) ON EPIDERMAL GROWTH FACTOR RECEPTOR - TYROSINE KINASE INHIBITORS (EGFR-TKIS) FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Zhang, T.
    Xu, J.
    Ma, J.
    Cai, S.
    Wu, C.
    Liu, Y.
    VALUE IN HEALTH, 2014, 17 (03) : A68 - A68
  • [32] Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma
    Das, Amit K.
    Chen, Benjamin P.
    Story, Nhchael D.
    Sato, Mitsuo
    Minna, John D.
    Chen, David J.
    Nirodi, Chaitanya S.
    CANCER RESEARCH, 2007, 67 (11) : 5267 - 5274
  • [33] Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer
    Cascone, T
    Morelli, MP
    Ciardiello, F
    ANNALS OF ONCOLOGY, 2006, 17 : 46 - 48
  • [34] Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
    Zwitter, Matjaz
    Rajer, Mirjana
    Stanic, Karmen
    Vrankar, Martina
    Doma, Andrej
    Cuderman, Anka
    Grmek, Marko
    Kern, Izidor
    Kovac, Viljem
    CANCER BIOLOGY & THERAPY, 2016, 17 (08) : 833 - 839
  • [35] CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS
    Nasu, Shingo
    Takata, So
    Masuhiro, Kentaro
    Morita, Satomu
    Iwata, Kaori
    Ryota, Noriko
    Okada, Yukari
    Tokuoka, Yoshie
    Ueda, Yuki
    Kumode, Akinori
    Usui, Naoko
    Tanaka, Ayako
    Shiroyama, Takayuki
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Hirashima, Tomonori
    RESPIROLOGY, 2017, 22 : 114 - 114
  • [36] Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for non-small cell lung cancer (NSCLC): A systematic review and meta-analysis
    Raphael, J.
    Vincent, M.
    Boldt, G.
    Shah, P.
    Rodrigues, G.
    Blanchette, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S77 - S77
  • [37] Mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC).
    Sonobe, M
    Katakura, H
    Adachi, T
    Wada, H
    Tanaka, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 637S - 637S
  • [38] Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore
    Chua, B.
    Tan, E. H.
    Lim, D. W-T.
    Ang, M-K.
    Tan, D. S. W.
    Ng, Q-S.
    Kanesvaran, R.
    Jain, A.
    Tan, W-L.
    Toh, C. K.
    Rajasekaran, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma
    Giuseppina Improta
    Angela Zupa
    Maria Iole Natalicchio
    Lorenza Sisinni
    Anna Marinaccio
    Giovanni Bozza
    Giulia Vita
    Michele Aieta
    Matteo Landriscina
    Medical Oncology, 2018, 35
  • [40] Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma
    Improta, Giuseppina
    Zupa, Angela
    Natalicchio, Maria Iole
    Sisinni, Lorenza
    Marinaccio, Anna
    Bozza, Giovanni
    Vita, Giulia
    Aieta, Michele
    Landriscina, Matteo
    MEDICAL ONCOLOGY, 2018, 35 (03)
12345